Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorZhongnan Hospital
About this trial
In this prospective study, the investigators will use integrated PET/CT with the agent 68Ga-FAPI and conventional imaging agent 18F-FDG to explore the application value of FAP-targeted molecular imaging in the diagnosis and staging for oral cancer. This study also aims to explore the application value of FAPI imaging in evaluating treatment response for oral cancer.
Eligibility criteria
Qualifiers
Voluntary participation with signed informed consent;
Aged 18~70 years;
Clinically highly suspected oral cancer and recurrence after treatment (Newly diagnosed patients: Scheduled for surgery or neoadjuvant therapy followed by surgery);
Ability to complete baseline and follow-up PET/CT (Follow-up FAPI PET/CT applies only to locally advanced patients undergoing neoadjuvant therapy.).
Disqualifiers
Pregnant or breastfeeding women, or women planning pregnancy during the trial period;
Known hypersensitivity to FAPI, FDG, or their components, or history of severe allergic reactions;
People with poor general condition, their heart, lung, liver, kidney and other important organ functions cannot tolerate surgery;
Before the injection of 18F-FDG, the fasting blood glucose level exceeded 11.0 mmol/L;
Trial design
Treatments tested in this trial
- 68Ga-DOTA-FAPI
- PET/CT
- Participants receive baseline paired FDG and FAPI PET/CT. For resectable locally advanced cases receiving neoadjuvant therapy undergo follow-up FAPI PET imaging.
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov